CTT Pharmaceutical Holdings, Inc. Logo

CTT Pharmaceutical Holdings, Inc.

CTTH

(1.0)
Stock Price

0,06 USD

-224.65% ROA

500.74% ROE

-0.42x PER

Market Cap.

627.661,00 USD

0% DER

0% Yield

0% NPM

CTT Pharmaceutical Holdings, Inc. Stock Analysis

CTT Pharmaceutical Holdings, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

CTT Pharmaceutical Holdings, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (1.59x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 ROE

Negative ROE (-313.72%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-224.65%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

CTT Pharmaceutical Holdings, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

CTT Pharmaceutical Holdings, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

CTT Pharmaceutical Holdings, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

CTT Pharmaceutical Holdings, Inc. Revenue
Year Revenue Growth
1999 15.537
2000 1 -1553600%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 760 100%
2006 3.040 75%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2018 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

CTT Pharmaceutical Holdings, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2018 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

CTT Pharmaceutical Holdings, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 1.323.837 100%
2009 787.942 -68.01%
2010 928.848 15.17%
2011 757.935 -22.55%
2012 336.165 -125.47%
2013 -107.155 413.72%
2014 545.402 119.65%
2015 1.445.011 62.26%
2018 4.358.624 66.85%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

CTT Pharmaceutical Holdings, Inc. EBITDA
Year EBITDA Growth
1999 -259.099
2000 -765.751 66.16%
2001 -67.491 -1034.6%
2002 -464.052 85.46%
2003 -1.064.564 56.41%
2004 -4.620.112 76.96%
2005 -1.596.179 -189.45%
2006 -962.450 -65.85%
2007 -2.604.142 63.04%
2008 -1.377.958 -88.99%
2009 -113.336 -1115.82%
2010 -2.458.141 95.39%
2011 -5.247.714 53.16%
2012 -1.186.573 -342.26%
2013 75.583 1669.89%
2014 -1.572.162 104.81%
2015 -1.445.880 -8.73%
2018 -4.357.268 66.82%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

CTT Pharmaceutical Holdings, Inc. Gross Profit
Year Gross Profit Growth
1999 -60.664
2000 1 6066500%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 760 100%
2006 -7.660 109.92%
2007 0 0%
2008 -71.624 100%
2009 -27.577 -159.72%
2010 -1.070.931 97.42%
2011 0 0%
2012 -758.742 100%
2013 0 0%
2014 0 0%
2015 0 0%
2018 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

CTT Pharmaceutical Holdings, Inc. Net Profit
Year Net Profit Growth
1999 -259.404
2000 -772.250 66.41%
2001 -67.251 -1048.31%
2002 -520.242 87.07%
2003 -1.133.197 54.09%
2004 -561.153 -101.94%
2005 -1.844.219 69.57%
2006 -1.255.584 -46.88%
2007 -2.761.455 54.53%
2008 -1.579.801 -74.8%
2009 -1.629.281 3.04%
2010 -1.097.720 -48.42%
2011 3.738.515 129.36%
2012 -1.003.188 472.66%
2013 110.464 1008.16%
2014 227.838 51.52%
2015 -1.445.880 115.76%
2018 -4.363.948 66.87%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

CTT Pharmaceutical Holdings, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 -54
2000 -97 44.33%
2001 -5 -2325%
2002 -1 -300%
2003 -3 50%
2004 -1 -100%
2005 -3 66.67%
2006 -2 -50%
2007 -4 50%
2008 -2 -100%
2009 -2 0%
2010 -1 -100%
2011 4 125%
2012 -1 500%
2013 0 0%
2014 0 0%
2015 0 0%
2018 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

CTT Pharmaceutical Holdings, Inc. Free Cashflow
Year Free Cashflow Growth
1999 -146.551
2000 -117.438 -24.79%
2001 -81 -144885.19%
2002 -766.289 99.99%
2003 -1.786.108 57.1%
2004 -2.596.921 31.22%
2005 -1.765.834 -47.06%
2006 -669.600 -163.71%
2007 -1.476.161 54.64%
2008 -605.934 -143.62%
2009 -513.285 -18.05%
2010 -1.781.138 71.18%
2011 -316.132 -463.42%
2012 -1.027.011 69.22%
2013 -136.229 -653.89%
2014 -72.250 -88.55%
2015 -13.535 -433.8%
2018 -105.715 87.2%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

CTT Pharmaceutical Holdings, Inc. Operating Cashflow
Year Operating Cashflow Growth
1999 -146.551
2000 -104.986 -39.59%
2001 -81 -129512.35%
2002 -549.082 99.99%
2003 -1.171.753 53.14%
2004 -1.598.437 26.69%
2005 -1.526.059 -4.74%
2006 -665.550 -129.29%
2007 -1.437.926 53.71%
2008 -605.934 -137.31%
2009 -513.285 -18.05%
2010 -1.781.138 71.18%
2011 -316.132 -463.42%
2012 -1.027.011 69.22%
2013 -136.229 -653.89%
2014 -72.250 -88.55%
2015 -13.535 -433.8%
2018 -105.715 87.2%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

CTT Pharmaceutical Holdings, Inc. Capital Expenditure
Year Capital Expenditure Growth
1999 0
2000 12.452 100%
2001 0 0%
2002 217.207 100%
2003 614.355 64.64%
2004 998.484 38.47%
2005 239.775 -316.43%
2006 4.050 -5820.37%
2007 38.235 89.41%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2018 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

CTT Pharmaceutical Holdings, Inc. Equity
Year Equity Growth
1999 -83.445
2000 -87.849 5.01%
2001 -17.608 -398.92%
2002 -577.761 96.95%
2003 -1.710.958 66.23%
2004 1.918.427 189.19%
2005 74.208 -2485.2%
2006 765.026 90.3%
2007 557.862 -37.14%
2008 151.388 -268.5%
2009 -1.248.672 112.12%
2010 -317.888 -292.8%
2011 456.450 169.64%
2012 -386.334 218.15%
2013 -243.126 -58.9%
2014 586.630 141.44%
2015 335.133 -75.04%
2018 659.411 49.18%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

CTT Pharmaceutical Holdings, Inc. Assets
Year Assets Growth
1999 4.005
2000 102 -3826.47%
2001 21 -385.71%
2002 398.341 99.99%
2003 1.613.557 75.31%
2004 2.169.442 25.62%
2005 2.158.151 -0.52%
2006 1.727.609 -24.92%
2007 1.858.776 7.06%
2008 1.549.420 -19.97%
2009 1.075.209 -44.1%
2010 1.262.276 14.82%
2011 4.182.995 69.82%
2012 203.079 -1959.79%
2013 6.252 -3148.22%
2014 1.662.370 99.62%
2015 643.617 -158.29%
2018 995.931 35.38%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

CTT Pharmaceutical Holdings, Inc. Liabilities
Year Liabilities Growth
1999 87.450
2000 87.951 0.57%
2001 17.629 -398.9%
2002 976.102 98.19%
2003 3.324.515 70.64%
2004 251.015 -1224.43%
2005 2.083.943 87.95%
2006 962.583 -116.49%
2007 1.300.914 26.01%
2008 1.398.032 6.95%
2009 2.323.881 39.84%
2010 1.260.929 -84.3%
2011 3.726.545 66.16%
2012 589.413 -532.25%
2013 249.378 -136.35%
2014 1.075.740 76.82%
2015 308.484 -248.72%
2018 336.520 8.33%

CTT Pharmaceutical Holdings, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.07
Price to Earning Ratio
-0.42x
Price To Sales Ratio
0x
POCF Ratio
-45.33
PFCF Ratio
-46.37
Price to Book Ratio
1.83
EV to Sales
0
EV Over EBITDA
-0.43
EV to Operating CashFlow
-46.3
EV to FreeCashFlow
-46.3
Earnings Yield
-2.36
FreeCashFlow Yield
-0.02
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.16
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0.07
Income Quality
0.01
ROE
-3.14
Return On Assets
-2486.68
Return On Capital Employed
2.84
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-4.31
Return on Tangible Assets
-2.25
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,02
Tangible Book Value per Share
0.02
Shareholders Equity per Share
0.02
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0
Current Ratio
2.09
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

CTT Pharmaceutical Holdings, Inc. Dividends
Year Dividends Growth

CTT Pharmaceutical Holdings, Inc. Profile

About CTT Pharmaceutical Holdings, Inc.

CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company's technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered wafer, an orally administrable wafer comprising at least one physiologically acceptable film forming agent. The company was formerly known as Mindesta Inc. and changed its name to CTT Pharmaceutical Holdings, Inc. in July 2015. The company is based in Ottawa, Canada.

CEO
Ryan Khouri
Employee
2
Address
429 Kent Street unit 112
Ottawa, K2P 2B4

CTT Pharmaceutical Holdings, Inc. Executives & BODs

CTT Pharmaceutical Holdings, Inc. Executives & BODs
# Name Age
1 Mr. Marc Lakmaaker
Special Advisor & Senior Vice President of Commercial Development
70
2 Ryan Khouri
Chief Executive Officer
70

CTT Pharmaceutical Holdings, Inc. Competitors

Choom Holdings Inc. Logo
Choom Holdings Inc.

CHOOF

(1.8)
Wayland Group Corp. Logo
Wayland Group Corp.

MRRCF

(0.0)
Beleave Inc. Logo
Beleave Inc.

BLEVF

(0.0)
Sunniva Inc. Logo
Sunniva Inc.

SNNVF

(2.2)